Nevertheless, as Usp22 deletion in vivo caused strong defects in various Ig isotypes but less so to IgA, Usp22 could be exploited as a therapeutic target in IgG or IgE-mediated autoimmune diseases, such as systemic lupus erythematosus, autoimmune thrombocytopenia, and asthma. Here, CD79A is linked to autoimmune thrombocytopenia.